Mary Y. Murphy

A diverse range of gene products are effectors of the type I interferon antiviral response

John W. Schoggins, Sam J. Wilson, Maryline Panis et al. · Nature · 2011 · 2.5K citations

Life Sciences, Immunology, Molecular Biology +16

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

Rikke Holmgaard, David Schaer, Yanxia Li et al. · Journal for ImmunoTherapy of Cancer · 2018 · 369 citations · Full text

Life Sciences, Immunology, Oncology +17

Dengue reporter viruses reveal viral dynamics in interferon receptor-deficient mice and sensitivity to interferon effectors in vitro

John W. Schoggins, Marcus Dorner, Michael Feulner et al. · Proceedings of the National Academy of Sciences · 2012 · 185 citations · Full text

Life Sciences, Infectious Diseases, Molecular Biology +17

Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy

Rikke Holmgaard, Alexandra Brachfeld, Billel Gasmi et al. · OncoImmunology · 2016 · 77 citations · Full text

Medicine, Immunology, Oncology +17

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

Yiwen Li, Carmine Carpenito, George Wang et al. · Journal for ImmunoTherapy of Cancer · 2018 · 31 citations · Full text

Life Sciences, Immunology, Oncology +17